NURIX THERAPEUTICS, INC. (NRIX) Current Ratio
- Current ratio · latest quarter: Value 6.34×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.34× | Current assets / current liabilities. $456.48M ÷ $72.02M ≈ 6.34× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 456.48M USD | Assets, Current |
| Current obligations | 72.02M USD | Liabilities, Current |
| Cash and equivalents | 67.69M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 12.21M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $456.48M | $72.02M | $67.69M | (m) | (m) | (m) | $12.21M | (m) | 6.34× |
| 2026-02-28 | $554.39M | $92.20M | $71.19M | (m) | (m) | (m) | $10.29M | (m) | 6.01× |
| 2025-11-30 | $606.82M | $86.47M | $246.96M | (m) | (m) | (m) | $11.21M | (m) | 7.02× |
| 2025-08-31 | $440.60M | $82.35M | $78.44M | (m) | (m) | (m) | $8.61M | (m) | 5.35× |
| 2025-05-31 | $515.33M | $75.61M | $84.26M | (m) | $19.00M | (m) | $5.95M | (m) | 6.82× |
| 2025-02-28 | $563.70M | $89.99M | $75.92M | (m) | (m) | (m) | $8.40M | (m) | 6.26× |
| 2024-11-30 | $619.39M | $95.85M | $110.00M | (m) | (m) | (m) | $11.48M | (m) | 6.46× |
| 2024-08-31 | $456.04M | $86.30M | $99.04M | (m) | (m) | (m) | $3.92M | (m) | 5.28× |
| 2024-05-31 | $450.22M | $80.78M | $116.79M | (m) | (m) | (m) | $2.81M | (m) | 5.57× |
| 2024-02-29 | $250.97M | $87.62M | $49.81M | (m) | (m) | (m) | $5.92M | (m) | 2.86× |
| 2023-11-30 | $295.50M | $86.96M | $54.63M | (m) | (m) | (m) | $6.40M | (m) | 3.40× |
| 2023-08-31 | $267.95M | $61.49M | $42.30M | $216.55M | $2.00M | (m) | $2.19M | (m) | 4.36× |
| 2023-05-31 | $290.01M | $72.26M | $58.96M | $222.22M | (m) | (m) | $4.53M | (m) | 4.01× |
| 2023-02-28 | $288.33M | $64.88M | $33.57M | $243.57M | (m) | (m) | $5.63M | (m) | 4.44× |
| 2022-11-30 | $318.45M | $70.66M | $64.47M | (m) | (m) | (m) | $5.06M | (m) | 4.51× |
| 2022-08-31 | $354.87M | $67.50M | $47.56M | $296.92M | (m) | (m) | $6.05M | (m) | 5.26× |
| 2022-05-31 | $306.79M | $72.67M | $41.53M | (m) | (m) | (m) | $6.14M | (m) | 4.22× |
| 2022-02-28 | $280.48M | $66.05M | $78.78M | (m) | (m) | (m) | $6.01M | (m) | 4.25× |
| 2021-11-30 | $311.12M | $66.26M | $80.51M | (m) | (m) | (m) | $6.65M | (m) | 4.70× |
| 2021-08-31 | $358.44M | $50.68M | $147.44M | (m) | (m) | (m) | $3.86M | (m) | 7.07× |
| 2021-05-31 | $396.28M | $46.84M | $188.21M | (m) | $2.54M | (m) | $5.41M | (m) | 8.46× |
| 2021-02-28 | $310.77M | $47.97M | $126.38M | (m) | (m) | (m) | $4.39M | (m) | 6.48× |
| 2020-11-30 | $298.43M | $44.54M | $119.36M | (m) | (m) | (m) | $3.41M | (m) | 6.70× |
| 2020-08-31 | $364.09M | $41.01M | $265.53M | (m) | (m) | (m) | $3.61M | (m) | 8.88× |
| 2019-11-30 | $39.35M | $16.14M | $34.82M | (m) | (m) | (m) | $1.60M | (m) | 2.44× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |